An interventional study of Manual FiO2 titration with Philips oximeter (SpO2 target 90%) and Manual FiO2 titration with Nonin oximeter (SpO2 target 90%) in Oxygen Delivery, Acute Respiratory Failure and High Flow Oxygen Therapy, sponsored by Laval University. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-09.
Sponsored by Laval University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Respiratory Insufficiency with a site in Canada — 24 open to participants now, 29 under way, 1 of them phase 3. Respiratory Insufficiency · Canada.
Among the 94 studies in Respiratory Insufficiency with a site in Canada, this one is the 34th largest by planned enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2025, is one of 46 with no phase, reaches primary completion later than 21 of the 28 other live ones, and was the 91st registered.
1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.
Browse Respiratory Insufficiency studies →24 of the 94 studies in Respiratory Insufficiency with a site in Canada are open now. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+
University of Alberta · Sites in Canada
Ages 18+
Lorenzo delSorbo · Sites in Canada
Ages 18+
Laval University · Sites in Canada
Ages 18+
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 12 · Phase 4 1
First in 1995; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 60 across 861 interventional studies indexed under Respiratory Insufficiency.
Median enrollment 31 across the 66 interventional studies, 118 across the 28 observational. Of the 54 that completed or were terminated, 5 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 94 have an industry lead sponsor. The 10 most frequent:
Laval University is the lead sponsor of 380 studies on the registry; 67 are open to participants now.
Laval University has 8 studies filed under Respiratory Insufficiency — fewer than ten, so there is no comparison to draw.
11 of the studies in Respiratory Insufficiency with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07518862University Health Network, TorontoHeart Rate VAriability as a MaRker for tItrATing hIgh flOw Nasal Cannula Therapy | 2026-11 |
| NCT04524585University Health Network, TorontoPartial Neuromuscular Blockade in Acute Hypoxemic Respiratory Failure | 2026-12-01 |
| NCT07359261University of AlbertaTranspulmonary Assessment for Individualized Lung Optimization in Obese Patients | 2026-12-31 |
| NCT07334379Lorenzo delSorboInterleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study | 2027-02-20 |
| NCT05440851University Health Network, TorontoPlatform of Randomized Adaptive Clinical Trials in Critical Illness | 2027-03-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 94 studies in Respiratory Insufficiency with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Several factors can influence oxygenation monitoring and respiratory support through oxygen therapy: the type of oximeter used, skin pigmentation, and the oxygenation target. It is essential to have an accurate measurement of SpO2 in order to optimize the flow of oxygen or FiO2 administered to patients. The question arises as to the impact of these confounding factors on the FiO2 set during high-flow nasal oxygen therapy. The aim of the study is to evaluate the impact of the oxygenation target and the oximeter used on FiO2 in patients receiving high-flow nasal oxygen therapy.
The oximeters evaluated will be the Nonin (Plymouth, MN) and the Philips (Eindhoven, Netherlands). Two SpO2 targets will be evaluated: 90% and 94%.
A total of four 10-minute periods will be performed in randomized order: Nonin 90, Nonin 94, Philips 90, and Philips 94.
At the end of each 10-minute period, arterial gas will be collected through the arterial catheter.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
During this periods , oxygen through high flow nasal therapy a will be administered in an manual titration to reach 90% of SpO2.
Device: Manual FiO2 titration with Nonin oximeter (SpO2 target 90%)
During this periods , oxygen through high flow nasal therapy a will be administered in an manual titration to reach 90% of SpO2.
Device: Manual FiO2 titration with Philips oximeter (SpO2 target 90%)
During this periods , oxygen through high flow nasal therapy a will be administered in an manual titration to reach 94% of SpO2.
Device: Manual FiO2 titration with Nonin oximeter (SpO2 target 94%)
During this periods , oxygen through high flow nasal therapy a will be administered in an manual titration to reach 94% of SpO2.
Device: Manual FiO2 titration with Philips oximeter (SpO2 target 94%)
FiO2 titration to reach the SpO2 target (set at 90%) with Philips oximeter
FiO2 titration to reach the SpO2 target (set at 90%) with Nonin oximeter
FiO2 titration to reach the SpO2 target (set at 94%) with Philips oximeter
FiO2 titration to reach the SpO2 target (set at 94%) with Nonin oximeter
FiO2
FiO2 at the end of each study period (last minute average) to reach SpO2 target to reach SpO2 target with specific oximeter
Time frame: Mean FiO2 in the two last minute of each study period between minute 8 and 10
Difference between SpO2 and SaO2
Difference (%) between SpO2 from each oximeter and SaO2 (% of SaO2 overestimation and underestimation for each oximeter)
Time frame: assessed up to 10 minutes - at the same of the arterial blood gases punction
High flow weaning criteria
Percentage of patient whose average FiO2 level below 40%
Time frame: Mean FiO2in the two last minute of each study period (between minute 8 and 10)
Intensive care unit transfert criteria
Percentage of patients whose average FiO2 level over 60%
Time frame: Mean FiO2in the two last minute of each study period (between minute 8 and 10)
Intubation criteria
Percentage of patients whose average FiO2 level over 80%
Time frame: Mean FiO2in the two last minute of each study period (between minute 8 and 10)
Mean difference on oxymeter
Mean (±SD) of the gaps between the different oximeters tested
Time frame: assessed up to 10 minutes - at the same of the arterial blood gases punction
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Jun 2027, 20 months after the start.
Of 360 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 20 months is below that.
Counting every sponsor, half of 376 studies reached it within 24 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.